Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Liabilities: 2014-2024

Historic Total Liabilities for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to $90.7 million.

  • Spyre Therapeutics' Total Liabilities fell 47.17% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year decrease of 47.17%. This contributed to the annual value of $90.7 million for FY2024, which is 23.73% up from last year.
  • According to the latest figures from FY2024, Spyre Therapeutics' Total Liabilities is $90.7 million, which was up 23.73% from $73.3 million recorded in FY2023.
  • Spyre Therapeutics' 5-year Total Liabilities high stood at $90.7 million for FY2024, and its period low was $20.8 million during FY2022.
  • Its 3-year average for Total Liabilities is $61.6 million, with a median of $73.3 million in 2023.
  • As far as peak fluctuations go, Spyre Therapeutics' Total Liabilities declined by 19.80% in 2022, and later surged by 251.69% in 2023.
  • Yearly analysis of 5 years shows Spyre Therapeutics' Total Liabilities stood at $21.8 million in 2020, then grew by 19.27% to $26.0 million in 2021, then decreased by 19.80% to $20.8 million in 2022, then soared by 251.69% to $73.3 million in 2023, then climbed by 23.73% to $90.7 million in 2024.